Compare NBIX & RBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NBIX | RBC |
|---|---|---|
| Founded | 1992 | 1919 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.7B | 15.8B |
| IPO Year | 1996 | 2005 |
| Metric | NBIX | RBC |
|---|---|---|
| Price | $167.43 | $486.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 28 | 10 |
| Target Price | $208.11 | ★ $608.11 |
| AVG Volume (30 Days) | ★ 1.3M | 345.7K |
| Earning Date | 11-02-2026 | 10-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.95 | 18.05 |
| EPS | 5.26 | ★ 6.16 |
| Revenue | $161,626,000.00 | ★ $1,870,900,000.00 |
| Revenue This Year | $39.52 | $14.73 |
| Revenue Next Year | $14.81 | $10.76 |
| P/E Ratio | ★ $32.28 | $79.50 |
| Revenue Growth | ★ 977.51 | 14.34 |
| 52 Week Low | $122.14 | $418.05 |
| 52 Week High | $186.12 | $667.69 |
| Indicator | NBIX | RBC |
|---|---|---|
| Relative Strength Index (RSI) | 66.05 | 48.22 |
| Support Level | $152.67 | $465.06 |
| Resistance Level | $169.57 | $500.93 |
| Average True Range (ATR) | 5.47 | 16.11 |
| MACD | 2.07 | 1.73 |
| Stochastic Oscillator | 80.70 | 62.58 |
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
RBC Bearings is an international manufacturer and marketer of engineered precision bearings, components, and essential systems for the industrial, defense, and aerospace industries. The offering includes plain bearings, roller bearings, ball bearings, and engineered products. The company has two reportable segments: industrial, which generates the most revenue, and aerospace and defense. The A&D segment represents the end markets for the company's engineered bearings and precision components used in commercial aerospace, defense aerospace, and sea and ground defense applications; and the industrial segment represents the end markets for its products used in various industrial applications. Geographically, the company generates a majority of its revenue from the United States.